(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.23% ¥ 2 630.00
Live Chart Being Loaded With Signals
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...
Stats | |
---|---|
Объем за сегодня | 857 100 |
Средний объем | 1.29M |
Рыночная капитализация | 1 413.91B |
EPS | ¥0 ( 2024-02-06 ) |
Дата следующего отчета о доходах | ( ¥28.50 ) 2024-05-07 |
Last Dividend | ¥27.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.39 |
ATR14 | ¥1.147 (0.04%) |
Объем Корреляция
Kyowa Kirin Co., Ltd. Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Kyowa Kirin Co., Ltd. Корреляция - Валюта/Сырье
Kyowa Kirin Co., Ltd. Финансовые показатели
Annual | 2023 |
Выручка: | ¥442.23B |
Валовая прибыль: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2023 |
Выручка: | ¥442.23B |
Валовая прибыль: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2022 |
Выручка: | ¥398.37B |
Валовая прибыль: | ¥311.46B (78.18 %) |
EPS: | ¥99.68 |
FY | 2021 |
Выручка: | ¥352.25B |
Валовая прибыль: | ¥264.40B (75.06 %) |
EPS: | ¥97.20 |
Financial Reports:
No articles found.
Kyowa Kirin Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2000-03-28 |
Last Dividend | ¥27.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | ¥539.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.32 | |
Div. Directional Score | 9.55 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9434.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8086.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7416.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6632.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
5958.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4659.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3896.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3116.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2002.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9997.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.184 | 1.500 | 6.33 | 9.49 | [0 - 0.5] |
returnOnAssetsTTM | 0.0791 | 1.200 | 7.36 | 8.83 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.358 | -1.000 | 6.42 | -6.42 | [0 - 1] |
currentRatioTTM | 4.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.93 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.03 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0232 | -1.500 | 9.61 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 535.43 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0285 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.962 | 0.962 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.230 | 1.000 | 7.40 | 7.40 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.84 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.42 | 1.000 | 8.34 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 9.99 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.13 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.358 | 1.500 | 6.42 | -6.42 | [0 - 1] |
pegRatioTTM | 0.426 | 1.500 | -0.491 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.261 | 1.000 | 5.97 | 0 | [0.1 - 0.5] |
Total Score | 6.32 |
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа